Pharmacokinetics of sacituzumab govitecan (IMMU-132) in patients with diverse advanced solid tumors

Trial Profile

Pharmacokinetics of sacituzumab govitecan (IMMU-132) in patients with diverse advanced solid tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Apr 2017

At a glance

  • Drugs Sacituzumab govitecan (Primary)
  • Indications Solid tumours
  • Focus Pharmacokinetics
  • Most Recent Events

    • 12 Apr 2017 New trial record
    • 05 Apr 2017 Results presented at the 108th Annual Meeting of the American Association for Cancer Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top